文献速递类风湿关节炎

风湿病患者对静脉用生物制剂的看法

Patient Perspectives on Intravenous Biologics for Rheumatologic Disease.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-08-07

两项调查评估风湿病患者对生物制剂静脉或皮下给药途径的看法。调查一纳入243例风湿病患者,调查二纳入BioAdvance项目中1598例患者(含306例风湿病患者)。结果显示生物制剂初治患者多数愿意接受皮下或静脉治疗,风湿病患者对静脉治疗的满意度评分从首次输注前的5分升至多次输注后的9分。

要点

  • 生物制剂初治患者中56%愿意接受皮下或静脉治疗中的任一种。
  • 生物制剂初治女性比男性更可能表达对给药途径的偏好。
  • 风湿病患者对静脉治疗的好感度中位评分从首次输注前的5分升至多次输注后的9分。

核心结论

  • 调查结果表明类风湿关节炎患者通常愿意接受静脉治疗,并对静脉治疗表达高度满意。
  • 作者认为额外的患者和提供者教育可能改善生物制剂给药方案共同决策。

研究设计与样本

  • 调查一在纽约布法罗一家风湿病诊所评估患者对生物制剂治疗的偏好。
  • 调查二询问加拿大BioAdvance患者支持项目中计划接受静脉生物制剂治疗的患者对静脉治疗的看法。

主要发现

  • 调查一243例风湿病患者中位年龄60岁,76%为女性,44%未接受过生物制剂治疗。
  • 调查一生物制剂初治患者中多数(56%)愿意接受皮下或静脉治疗,生物制剂初治女性比男性更可能表达对给药途径的偏好。
  • 调查二1598例患者(含306例风湿病患者)完成完整调查,风湿病患者中位年龄49岁,58%为女性,61%在入组BioAdvance项目前未使用过生物制剂。
  • 调查二风湿病患者回忆的静脉治疗好感度中位评分在首次项目输注前为5分,多次治疗输注后升至9分(10分制,分数越高好感度越高)。

关键数值与推荐

  • 静脉治疗好感度采用10分制,分数越高表示好感度越高。
  • 风湿病患者首次输注前好感度中位评分为5分,多次输注后为9分。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Two surveys were conducted with patients with rheumatologic diseases to evaluate perceptions of different routes of administration (intravenous [IV] or subcutaneous [SC]) for biologic therapy. METHODS: In Survey I, patient preferences toward biologic treatment were evaluated at a rheumatology practice in Buffalo, New York. In Survey II, Canadian patients enrolled in the BioAdvance patient support program and scheduled to receive IV biologic therapy were asked about their opinions of IV treatment. RESULTS: In Survey I, 243 rheumatology patients participated. Median patient age was 60 years, 76% were female, and 44% were naive to treatment with biologic agents. Among biologic-naive patients, the majority (56%) were open to either SC or IV treatment; biologic-naive women were more likely than men to express a preference for the route of administration. In Survey II, 1,598 patients from the BioAdvance program (including 306 rheumatology patients) completed the full survey. Among the rheumatology patients, the median age was 49 years, 58% were female, and 61% had not previously taken biologics before enrolling in the BioAdvance program. The median rating of IV favorability (on a 10-point scale, with higher numbers indicating increased favorability) recalled by rheumatology patients was 5 prior to their first program infusion, which increased to 9 after multiple treatment infusions. CONCLUSION: These survey results indicate that patients with rheumatoid arthritis are generally open to IV treatment and express high satisfaction with IV therapy. Additional patient and provider education may improve shared decision-making regarding biologic therapy administration options.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Grisanti L, Kwiatkowski A, Dyrda P, et al. Patient Perspectives on Intravenous Biologics for Rheumatologic Disease. Arthritis Care Res (Hoboken). 2019. PMID: 30221490. doi:10.1002/acr.23758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。